Second positive phase 3 dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

Tarrytown, n.y. and paris, jan. 19, 2022 /prnewswire/ -- dupixent is the first and only medicine to demonstrate positive phase 3 results in prurigo nodularis, confirming the potential benefit of targeting il-4 and il-13, central drivers of type 2 inflammation, to address itch and skin lesions data confirm results from first phase 3 trial, with 60% of dupixent patients meeting the primary endpoint of itch reduction compared to 18% of placebo patients at 24 weeks additionally, nearly three times as many dupixent patients experienced reduced skin lesions data continue to support well-established safety profile of dupixent regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced positive pivotal results from a second phase 3 trial, prime, evaluating dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease.
REGN Ratings Summary
REGN Quant Ranking